Company news
Rakovina Therapeutics Inc news in 2025
Rakovina Therapeutics Inc's news releases, calls and decks from 2025, newest first.
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
December 17, 2025
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
December 10, 2025
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
December 1, 2025
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
November 28, 2025
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
November 24, 2025
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
November 24, 2025
Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
November 18, 2025
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
November 10, 2025
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
October 27, 2025
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
October 16, 2025
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
August 28, 2025
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
August 26, 2025
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
August 12, 2025
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
July 30, 2025
Rakovina Therapeutics Announces Stock Option Grants
July 29, 2025
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
July 24, 2025
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
July 23, 2025
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
July 15, 2025
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award
July 11, 2025
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
July 10, 2025
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
June 30, 2025
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
June 30, 2025
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
June 25, 2025
Rakovina Therapeutics Announces Share Consolidation Effective Date
June 20, 2025
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
June 12, 2025
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
June 6, 2025
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
June 2, 2025
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
May 28, 2025
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
May 15, 2025
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
May 5, 2025
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
April 29, 2025
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
April 29, 2025
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
April 22, 2025
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum
March 25, 2025
Next-Gen Cancer Treatment: Rakovina's AI-Driven ATR Inhibitors Enter Preclinical Testing
March 12, 2025
Rakovina Therapeutics and Variational AI Strengthen Partnership
February 26, 2025
Decks in 2025
- Investor Presentation (November 2025)
Investor deck · 20 slides · November 2025
- Investor Presentation (July 2025)
Investor deck · 19 slides · July 2025
- Investor Presentation (May 2025)
Investor deck · 19 slides · May 2025
- Investor Presentation (May 2025)
Investor deck · 20 slides · May 2025
- Investor Presentation (January 2025)
Investor deck · 20 slides · January 2025